Organ systems

NEOGEN Launches Reveal® Q+ for Δ9-THC in Hemp

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Psychoactive drugs, Euphoriants, Appetite stimulants, Entheogens, Organ systems, Cannabis, Cannabinoids, Tetrahydrocannabinol, Hemp, Cannabidiol

NEOGEN's new Reveal Q+ for 9-THC can precisely detect and report THC levels between 0.1% and 1.6%, providing fast, reliable, and on-demand crop monitoring.

Key Points: 
  • NEOGEN's new Reveal Q+ for 9-THC can precisely detect and report THC levels between 0.1% and 1.6%, providing fast, reliable, and on-demand crop monitoring.
  • "The addition of the ability to test for 9-THC to our Reveal Q+ portfolio puts the power in the hands of hemp farmers," says John Adent, NEOGEN's President and CEO.
  • Hemp has various uses, including rope and textiles, feed and grain, and cannabidiol (CDB), commonly used in body care products and supplements.
  • NEOGEN Corporation develops and markets comprehensive solutions dedicated to food and animal safety.

Global Cannabidiol Market Size Expected to Reach $2.8 Billion by 2028 with a CAGR of 21%

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Organ systems, Psychoactive drugs, Cannabinoids, Resorcinols, Appetite stimulants, Entheogens, Euphoriants, Cannabidiol, Cannabis, Hemp

PALM BEACH, Fla., July 28, 2021 /PRNewswire/ -- Cannabidiol derived from hemp is anticipated to witness rapid growth owing to increasing demand from the pharmaceutical sector and rising awareness among consumers regarding health. Increasing consumer disposable income along with the legalization of medicinal cannabis is anticipated to have a positive impact on the demand for cannabidiol in the pharmaceutical sector. Oils, tinctures, concentrate, capsules, topical solutions such as slaves, lip balms, lotions, and edibles such as baked goods, coffee, chocolates, gums, and candies are some of the CBD products which are in high demand. Due to its healing properties, the demand for cannabidiol (CBD) for health and wellness purposes is high, which is the major factor driving the market growth. In addition, the rising acceptance and use of products due to government approvals is a major factor expected to boost production for CBD-infused products.  A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.  Active Companies in the merchant industry include Grove, Inc. (NASDAQ: GRVI), Tilray, Inc. (NASDAQ: TLRY) (TSX: TLRY), Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED), Pressure BioSciences, Inc. (OTCQB: PBIO), cbdMD, Inc. (NYSE: YCBD).

Key Points: 
  • A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.
  • Grand View added: "Furthermore, the use of hemp-derived CBD is increasing rapidly owing to its anti-inflammatory, anti-aging, and antioxidant properties.
  • This rapidly progressing transformation of cannabidiol from herbal preparations to prescription drugs is anticipated to boost the growth of the market.
  • Furthermore, growing awareness about the medical benefits of cannabidiol, including its healing properties, is anticipated to drive the product demand in the pharmaceutical industry."

Cary Medical Management Announces Patient-Centered Focus to Treat Diabetes

Retrieved on: 
Wednesday, July 28, 2021
Diabetes, Clinical medicine, Medicine, Organ systems, Type 1 diabetes, Glycated hemoglobin, Type 2 diabetes, Diabetes management, Prediabetes

Reversal of type II diabetes can be defined by a reduction of a patient's HbA1C values to below 6.5 as stated by American Diabetes Association.

Key Points: 
  • Reversal of type II diabetes can be defined by a reduction of a patient's HbA1C values to below 6.5 as stated by American Diabetes Association.
  • Dr. Tse was able to reverse diabetes in most cases within three to six months, requiring minimal or no medications.
  • People with diabetes have medical expenses approximately 2.3 times higher than those who do not have diabetes.
  • It manages the Generations Family Practice , Rocky Mount Family Medical Center (RMFMC) and RSI Medical .

2021 Insights on Macular Degeneration Drugs in Development - Gain Strategic Competitor Information - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021
Health, General Health, Macular degeneration, Senescence, Organ systems, Conbercept

The "Macular Degeneration (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Macular Degeneration (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Macular Degeneration, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Macular Degeneration and features dormant and discontinued projects.
  • Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies.

Studies Show Sustained Acoustic Medicine Effectively Treats Shoulder Injuries

Retrieved on: 
Tuesday, July 27, 2021
Organ systems, Medical specialties, Pain, Clinical medicine, Soft tissue disorders, Overuse injuries, Shoulder, Musculoskeletal disorders, Shoulder problem, Myofascial pain syndrome, Analgesic

TRUMBULL, Conn., Jul 27, 2021 /PRNewswire/ --Two recently published studies found that the long-duration, wearable sustained acoustic medicine device from ZetrOZ Systems relieves pain from shoulder and other injuries when conservative therapies fail, and can be a replacement for pain medications.

Key Points: 
  • TRUMBULL, Conn., Jul 27, 2021 /PRNewswire/ --Two recently published studies found that the long-duration, wearable sustained acoustic medicine device from ZetrOZ Systems relieves pain from shoulder and other injuries when conservative therapies fail, and can be a replacement for pain medications.
  • "Sustained acoustic medicine gives doctors an additional way to treat musculoskeletal injuries and to treat post-operative pain, and avoid potentially addictive pain medications."
  • Sustained acoustic medicine provides an attractive home-use treatment option for patients suffering from upper trapezius myofascial pain."
  • The authorsconcluded that sustained acoustic medicine showed promise as a "self-applied effective therapy, and as a possible replacement or adjuvant to pharmacotherapies for shoulder pain."

Jiffy Lube® and Muscular Dystrophy Association Celebrate 10th Annual Fundraising Campaign to Support the Neuromuscular Community

Retrieved on: 
Tuesday, July 27, 2021
Amyotrophic lateral sclerosis, Muscular Dystrophy Association, Neurological disorders, Organ systems, Musculoskeletal disorders, Muscular dystrophy, MDA, Jiffy Lube, Jiffy, Dystrophy, Neuromuscular disease, Muscular Dystrophy Canada

During the month of August, Jiffy Lube customers will be invited to make a donation of$3or more to MDA at participating Jiffy Lube centers.

Key Points: 
  • During the month of August, Jiffy Lube customers will be invited to make a donation of$3or more to MDA at participating Jiffy Lube centers.
  • "I'm honored to support the Muscular Dystrophy Association and Jiffy Lube's efforts to fund breakthrough science and care and commend them for their decade-long dedication of driving to do more to support MDA's mission."
  • "I'm so happy to be part of the Jiffy Lube campaign, because it is raising awareness about muscular dystrophy that I live with," said Maddee Helaire, MDA Ambassador.
  • For decades, the Muscular Dystrophy Association (MDA) has been committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases.

PanOxyl® Proudly Introduces Oil Control Moisturizer with Mineral SPF 30 into Award-Winning Collection

Retrieved on: 
Tuesday, July 27, 2021
Organ systems, Acneiform eruptions, Dermatology, Skin care, Puberty, Integumentary system, Emollients and protectives, Acne cosmetica, Moisturizer, Acne, Comedo

The mattifying, noncomedogenic formulation of the PanOxyl Oil Control Moisturizer rubs gently into skin without clogging pores.

Key Points: 
  • The mattifying, noncomedogenic formulation of the PanOxyl Oil Control Moisturizer rubs gently into skin without clogging pores.
  • Absorbing excess oil, reducing shine, and replenishing moisture that is often stripped when using acne-control products, PanOxyl Oil Control Moisturizer is formulated specifically for oily, acne-prone skin.
  • The launch of the PanOxyl Oil Control Moisturizer with Mineral SPF 30 amplifies the consistent growth you can expect to see from this legacy brand and across the entire Crown portfolio."
  • PanOxyl Oil Control Moisturizer with Mineral SPF 30 is available via Amazon and at select major retailers nationwide.

ForwardVue Pharma Appoints Bob Katz as Chief Executive Officer

Retrieved on: 
Tuesday, July 27, 2021
Angiology, Angiogenesis, Macular degeneration, Medical specialties, Organ systems, Clinical medicine

BOSTON, July 27, 2021 /PRNewswire/ --ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.

Key Points: 
  • BOSTON, July 27, 2021 /PRNewswire/ --ForwardVue Pharma names Bob Katz as Chief Executive Officer to advance the pre-clinical development of potent long-acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.
  • Bob Katz is a seasoned life science executive bringing broad, multi-disciplinary expertise in early-stage technology development, clinical applications and successful fundraising.
  • Most recently, Katz was CEO and President of ContraMed where he directed the company from the pre-clinical stage to a successful Phase 3 Clinical Trial and exit.
  • Prior to ContraMed, Katz has held multiple C-level positions at venture-backed startups.

Global Non-Proliferative Diabetic Retinopathy (NPDR) Drugs in Development: 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Pharmaceutical, Health, Ophthalmology, Organ systems, Diabetes, Health, Retinopathy, Diabetic retinopathy, PDR

The "Non-Proliferative Diabetic Retinopathy (NPDR) (Metabolic Disorders) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Proliferative Diabetic Retinopathy (NPDR) (Metabolic Disorders) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of the Non-Proliferative Diabetic Retinopathy (NPDR) pipeline landscape.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Non-Proliferative Diabetic Retinopathy (NPDR) and features dormant and discontinued projects.
  • Devise corrective measures for pipeline projects by understanding Non-Proliferative Diabetic Retinopathy (NPDR) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Female Infertility Treatment Drugs Market by Therapy, Route of Administration, Distribution Channel, and Region - Global Size, Share, Outlook, and Opportunity Analysis, 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021
Women, Consumer, Health, Parenting, Pharmaceutical, Fertility medicine, Organ systems, Medical specialties, Women\'s health, Women's health, Ferring Pharmaceuticals, Infertility, Female infertility, Polycystic ovary syndrome, Pharmaceutical industry in China, Evotec

The "Female Infertility Treatment Drugs Market, by Therapy, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Female Infertility Treatment Drugs Market, by Therapy, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Market players are focusing on various growth strategies such as agreements, partnerships, and collaborations to accelerate the development of drugs for infertility treatment, which is expected to boost growth of the global female infertility treatment drugs market over the forecast period.
  • For instance, in January 2020, Bayer AG announced the expansion of their partnership with Evotec SE, a biotechnology company focusing on women health, with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS), which is one of the causes of infertility in females.
  • Moreover, in January 2019, Ferring Pharmaceuticals, a biopharmaceutical company entered into an exclusive agreement with Sun Pharmaceutical Industries Ltd., an India-based multinational pharmaceutical company to acquire the U.S. commercialization rights for a generic version of Ganirelix Acetate injection which is used for treatment of female infertility.